VTGN

Vistagen TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 7.2 / Value 57.6

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.2.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

— · Net —

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net —

Target $1.00

Why

Momentum7 · Δ7d -

Value58 · Δ7d -0.2

SentimentN/A · Δ7d -

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

-0.7

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 7.2 / Value 57.6

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$9.41M

Beta

0.32

Shares Out

41.03M

P/E (TTM) · Derived

-0.1

P/S (TTM)

38.64

P/FCF (TTM) · Derived

-0.13

Rev YoY

+29.5%

EPS YoY

-2.5%

Gross Margin

+42.3%

Op Margin

-8895.7%

Net Debt

-$44.36M

Current Ratio

3.67

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology